Increased Risk of Herpes Zoster in Young and Metabolically Healthy Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study
1
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: The risk of herpes zoster (HZ) among patients with inflammatory bowel disease (IBD) remains unclear in terms of age and metabolic comorbidities, including diabetes mellitus, hypertension, or dyslipidemia. We conducted a nationwide population-based study to investigate the risk of HZ in patients with IBD. Methods: From 2010 to 2013, a retrospective study was performed using claims data in Korea. We compared the incidence of HZ between 30,100 IBD patients (10,517 Crohn’s disease [CD] and 19,583 ulcerative colitis [UC] patients) and 150,500 non-IBD controls matched by age and sex. Results: During a mean follow-up of 5.0 years, incidence rates of HZ (per 1,000 person-years) were 13.60, 14.99, and 9.19 in the CD, UC, and control groups, respectively. The risk of HZ was significantly higher in patients with CD (adjusted hazard ratio [HR], 2.13; p<0.001) and UC (adjusted HR, 1.40; p<0.001) than in the controls. The impact of CD on developing HZ was significantly more prominent in younger patients (adjusted HR, 2.61 for age <15, whereas 1.39 for age ≥60; interaction p=0.001) and in patients without metabolic comorbidities (adjusted HR, 2.24, whereas 1.59 in those with metabolic comorbidities; interaction p=0.015). Moreover, the impact of UC on developing HZ significantly increased in younger patients (adjusted HR, 2.51 in age <15, whereas 1.22 in age ≥60; interaction p=0.014) and patients without metabolic comorbidities (adjusted HR, 1.49 whereas 1.16 in those with metabolic comorbidities; interaction p<0.001). Conclusions: IBD was associated with an increased risk of HZ, especially in younger patients without metabolic comorbidities.
Abstract
Background/Aims: The risk of herpes zoster (HZ) among patients with inflammatory bowel disease (IBD) remains unclear in terms of age and metabolic comorbidities, including diabetes mellitus, hypertension, or dyslipidemia. We conducted a nationwide population-based study to investigate the risk of HZ in patients with IBD. Methods: From 2010 to 2013, a retrospective study was performed using claims data in Korea. We compared the incidence of HZ between 30,100 IBD patients (10,517 Crohn’s disease [CD] and 19,583 ulcerative colitis [UC] patients) and 150,500 non-IBD controls matched by age and sex. Results: During a mean follow-up of 5.0 years, incidence rates of HZ (per 1,000 person-years) were 13.60, 14.99, and 9.19 in the CD, UC, and control groups, respectively. The risk of HZ was significantly higher in patients with CD (adjusted hazard ratio [HR], 2.13; p<0.001) and UC (adjusted HR, 1.40; p<0.001) than in the controls. The impact of CD on developing HZ was significantly more prominent in younger patients (adjusted HR, 2.61 for age <15, whereas 1.39 for age ≥60; interaction p=0.001) and in patients without metabolic comorbidities (adjusted HR, 2.24, whereas 1.59 in those with metabolic comorbidities; interaction p=0.015). Moreover, the impact of UC on developing HZ significantly increased in younger patients (adjusted HR, 2.51 in age <15, whereas 1.22 in age ≥60; interaction p=0.014) and patients without metabolic comorbidities (adjusted HR, 1.49 whereas 1.16 in those with metabolic comorbidities; interaction p<0.001). Conclusions: IBD was associated with an increased risk of HZ, especially in younger patients without metabolic comorbidities.
참고문헌 (40)
- Mahalingam R, "Latent varicella-zoster viral DNA in human trigeminal and thoracic ganglia", N Engl J Med, 323, pp.627~631 (1990)
- Cullen G, "Varicella zoster virus infection in inflammatory bowel disease", Inflamm Bowel Dis, 18, pp.2392~2403 (2012)
- Oxman MN, "A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults", N Engl J Med, 352, pp.2271~2284 (2005)
- Yawn BP, "A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction", Mayo Clin Proc, 82, pp.1341~1349 (2007)
- Lin YH, "Disease burden and epidemiology of herpes zoster in pre-vaccine Taiwan", Vaccine, 28, pp.1217~1220 (2010)
- 김유정, "Population-Based Study of the Epidemiology of Herpes Zoster in Korea", Journal of Korean Medical Science, 29(12), pp.1706~1710 (2014), 대한의학회
- Arvin A, "Aging, immunity, and the varicella-zoster virus", N Engl J Med, 352, pp.2266~2267 (2005)
- Kawai K, "Risk factors for herpes zoster : a systematic review and meta-analysis", Mayo Clin Proc, 92, pp.1806~1821 (2017)
- Joesoef RM, "Chronic medical conditions as risk factors for herpes zoster", Mayo Clin Proc, 87, pp.961~967 (2012)
- Esteban-Vasallo MD, "Sociodemographic characteristics and chronic medical conditions as risk factors for herpes zoster : a population-based study from primary care in Madrid(Spain)", Hum Vaccin Immunother, 10, pp.1650~1660 (2014)
- Gupta G, "Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease", Clin Gastroenterol Hepatol, 4, pp.1483~1490 (2006)
- Marehbian J, "Adverse events associated with common therapy regimens for moderateto-severe Crohn’s disease", Am J Gastroenterol, 104, pp.2524~2533 (2009)
- Jung YS, "Cancer risk in the early stages of inflammatory bowel disease in Korean patients : a nationwide population-based study", J Crohns Colitis, 11, pp.954~962 (2017)
- Ahn IM, "Incidence, prevalence, and survival of moyamoya disease in Korea : a nationwide, population-based study", Stroke, 45, pp.1090~1095 (2014)
- Khan N, "The severity of herpes zoster in inflammatory bowel disease patients treated with anti-TNF agents", Inflamm Bowel Dis, 24, pp.1274~1279 (2018)
- Côté-Daigneault J, "Management and prevention of herpes zoster in the immunocompromised inflammatory bowel disease patient : a clinical quandary", Inflamm Bowel Dis, 22, pp.2538~2547 (2016)
- Tsai SY, "Increased risk of varicella zoster virus infection in inflammatory bowel disease in an Asian population : a nationwide population-based cohort study", Int J Clin Pract, 69, pp.228~234 (2015)
- Long MD, "Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease", Aliment Pharmacol Ther, 37, pp.420~429 (2013)
- de Souza HS, "Immunopathogenesis of IBD : current state of the art", Nat Rev Gastroenterol Hepatol, 13, pp.13~27 (2016)
- Murphy KM, "Effector T cell plasticity : flexibility in the face of changing circumstances", Nat Immunol, 11, pp.674~680 (2010)
- Scott MG, "Spontaneous secretion of IgG subclasses by intestinal mononuclear cells : differences between ulcerative colitis, Crohn’s disease, and controls", Clin Exp Immunol, 66, pp.209~215 (1986)
- Yun H, "Risk of herpes zoster in autoimmune and inflammatory diseases : implications for vaccination", Arthritis Rheumatol, 68, pp.2328~2337 (2016)
- Herrero JI, "Herpes zoster after liver transplantation : incidence, risk factors, and complications", Liver Transpl, 10, pp.1140~1143 (2004)
- Tsai SY, "Increased risk of herpes zoster in patients with psoriasis: a population-based retrospective cohort study", PLoS One, 22(12), pp.e0179447~ (2017)
- Strangfeld A, "Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents", JAMA, 301, pp.737~744 (2009)
- Yang YW, "Risk of herpes zoster among patients with chronic obstructive pulmonary disease : a population-based study", CMAJ, 183, pp.E275~ (2011)[DOI]
- McDonald JR, "Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis", Clin Infect Dis, 48, pp.1364~1371 (2009)
- Hu SC, "Lymphopaenia, anti-Ro", anti-RNP autoantibodies, renal involvement and cyclophosphamide use correlate with increased risk of herpes zoster in patients with systemic lupus erythematosus, 2013, pp.93, 314~318
- Kim SY, "Tumor necrosis factor blockade and the risk of viral infection", Nat Rev Rheumatol, 6, pp.165~174 (2010)
- Liao TL, "Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications : a case-control study in Asia", BMJ Open, 7, pp.e014032~ (2017)
- Konstantinos H. Katsanos, "Inflammatory Bowel Disease: Updates on Molecular Targets for Biologics", Gut and Liver, 11(4), pp.455~463 (2017), 거트앤리버 소화기연관학회협의회
- Algood HM, "Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis", Clin Infect Dis, 41(Suppl 3), pp.S189~S193 (2005)
- Kindler V, "The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection", Cell, 56, pp.731~740 (1989)
- Dong Il Park, "Asian Organization for Crohn’s and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment", Intestinal research, 16(1), pp.4~16 (2018), 대한장연구학회
- 이장욱, "Clinical features of active tuberculosis that developed during anti-tumor necrosis factor therapy in patients with inflammatory bowel disease", Intestinal research, 14(2), pp.146~151 (2016), 대한장연구학회
- Chang K, "Increased risk of herpes zoster infection in patients with inflammatory bowel diseases in Korea", Clin Gastroenterol Hepatol, 16, pp.1928~1936 (2018)[DOI]
- 김지애, "Towards Actualizing the Value Potential of Korea Health Insurance Review and Assessment (HIRA) Data as a Resource for Health Research: Strengths, Limitations, Applications, and Strategies for Optimal Use of HIRA Data", Journal of Korean Medical Science, 32(5), pp.718~728 (2017), 대한의학회
- Levin MJ, "Varicella-zoster virusspecific immune responses in elderly recipients of a herpes zoster vaccine", J Infect Dis, 197, pp.825~835 (2008)
- Mills R, "Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster", Vaccine, 28, pp.4204~4209 (2010)
- 정윤석, "Insufficient Knowledge of Korean Gastroenterologists Regarding the Vaccination of Patients with Inflammatory Bowel Disease", Gut and Liver, 8(3), pp.242~247 (2014), 거트앤리버 소화기연관학회협의회